Abstract
This study aims to inform SARS-CoV-2 vaccine development/licensure/decision-making/implementation, using mathematical modeling, by determining key preferred vaccine product characteristics and associated population-level impacts of a vaccine eliciting long-term protection. A prophylactic vaccine with efficacy against acquisition (VES) ≥70% can eliminate the infection. A vaccine with VES <70% may still control the infection if it reduces infectiousness or infection duration among those vaccinated who acquire the infection, if it is supplemented with <20% reduction in contact rate, or if it is complemented with herd-immunity. At VES of 50%, the number of vaccinated persons needed to avert one infection is 2.4, and the number is 25.5 to avert one severe disease case, 33.2 to avert one critical disease case, and 65.1 to avert one death. The probability of a major outbreak is zero at VES ≥70% regardless of the number of virus introductions. However, an increase in social contact rate among those vaccinated (behavior compensation) can undermine vaccine impact. In addition to the reduction in infection acquisition, developers should assess the natural history and disease progression outcomes when evaluating vaccine impact.
Highlights
Following the Severe Acute Respiratory Syndrome (SARS) epidemic in 2002 and the Middle EastRespiratory Syndrome (MERS) epidemic in 2012 [1], a novel coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late December 2019 in Wuhan, Hubei province, China [2,3]
Other relevant characteristics include the duration of protection elicited by the vaccine and vaccination effect on adherence to social distancing; we investigated the impact of increasing social contact rate following vaccination with the perception of protection
In the first scenario (Figure 1 and Figures S2 and S3), where vaccination was scaled up to 80% coverage before epidemic onset, the epidemic in absence of vaccination peaked at 158 days after virus introduction but at 286 days when VEP1 = 50%, 452 days when VEI = 50%, and 462 days when vaccine with efficacy against acquisition (VES) = 50%
Summary
Following the Severe Acute Respiratory Syndrome (SARS) epidemic in 2002 and the Middle EastRespiratory Syndrome (MERS) epidemic in 2012 [1], a novel coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late December 2019 in Wuhan, Hubei province, China [2,3]. In the early stages of development, modeling is used to define the vaccine’s key preferred product characteristics by estimating levels of efficacy necessary to observe a significant population-level impact, determining the necessary duration of protection/immunity incurred by the vaccine, and identifying priority populations for optimal effectiveness [21,29,30]. These parameters provide early guidance to developers, manufacturers, regulators, and decision-makers about candidates that are likely to be optimal through specifying vaccine characteristics that will maximize public health impact and cost-effectiveness [21,28,29,31,32]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have